摘要
目的：对药品不良反应监测系统中的联用药品进行统计分析,探索联用药品分析方法。方法：以2012年1月~2013年6月淄博市上报的药品不良反应/事件报告数据为目标数据,对数据结构进行转换,采用严重不良反应构成比筛选联用药品风险。结果：1 421份存在联合用药的报告中,严重不良反应构成比为9.8%;9 477份单独用药的报告中,严重不良反应构成比3.9%,两者比较差异有统计学意义（P〈0.01）;通过严重不良反应构成比筛选,头孢曲松和炎琥宁的联合使用可能存在风险。结论：采用严重不良反应构成比筛选联用药品风险的方法可行,但需要将报告其他信息纳入分析,补充该方法的不足。
Objective：To explore the analysis method for drug combination in national adverse drug reaction monitoring data. Methods： The data in Zibo adverse drug reaction monitoring system received from January 2012 to June 2013 were retrieved. The drug combination information was analyzed according to the constituent ratio of serious adverse reactions after transforming the data structure. Results： The constituent ratio of serious adverse reaction in terms of the single drug using was 3.9% ,and the constituent ratio of serious adverse reaction in drug combination using was 9.8%. The difference was statistically significant（ P 〈 0.01 ）. It screened out the risk of combination of ceftriaxone and yanhuning with a special method. Conclusion：The analysis method based on the constituent ratio of serious adverse reactions was feasible for screening out the risk of drug combination, but it needed to be supplemented by bringing more information of ADR into it.
出处
《药物流行病学杂志》
CAS
2014年第5期302-304,共3页
Chinese Journal of Pharmacoepidemiology
关键词
药品不良反应
报告
监测数据
联合用药
Adverse drug reaction
Report
Monitoring data
Drug combination
